Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
about
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infectionsPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.New facets of antifungal therapy.Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation.New pharmacological opportunities for the treatment of invasive mould diseases.Posaconazole in lung transplant recipients: use, tolerability, and efficacy.Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections.Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.Mucormycosis in Children: Review and Recommendations for Management.Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies.Posaconazole liquid vs tablet formulation in lung transplant recipients.Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.Hepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents.Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignanciesClinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
P2860
Q26771180-4F70B491-2771-4A55-ACF9-634C2331F504Q34532546-1DA3C7E0-42DB-4F96-BB33-90FC68C40E0BQ36406975-BA6EA22D-8259-4CEA-B29C-84C93BCEF098Q37203849-5A5663E4-E650-4BE5-B490-8984DBCFEFC4Q38784762-D213AF55-F0B5-49CF-BB72-8AF463BC072CQ38797864-9430E22F-43C7-4047-A188-8E540142DAEFQ39026820-D6EE14E8-3D74-4E32-AF85-438C2C33BCA2Q39553916-32DFD7D8-5FFE-45D8-9D10-65B78140BA43Q40140538-4EA1787E-DC52-411A-B680-D8D2D8ED4192Q40273481-1E108FDB-88D1-4FC5-80AB-2DEFB1C2BAC8Q40827808-B56CC7B7-755A-49C9-9721-28D9C70902CEQ40841377-B0F4F0BF-8043-486E-8508-965D1D4E99D8Q41284722-6E731F45-9A4A-4082-AAFA-E1B4B72A3806Q42563983-1FCC8D70-A72E-4EA0-BF58-5CA11B859158Q47222680-ECE40837-24BC-4709-8E26-A8612BC24E8EQ47950887-8499F628-8A4F-4E1C-8AD0-D6805A04A90AQ48157814-CC19D931-89DF-448E-B325-5A5092D71468Q48354018-DF6524D1-A29C-4B0D-AA92-B3FD12DDEF18Q50049061-1FF45E9F-BF69-4DDC-AF05-3B05A78666C4Q52698203-BDDCAA49-E8D8-4EE3-A8BD-6F2FAC65AD43Q57518392-894521D0-2000-4438-A67D-F286706B4F59Q58701142-0D7C290C-29E5-42EA-BCB1-A0DA06FB7F09
P2860
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Superior Serum Concentrations ...... in Hematological Malignancies.
@ast
Superior Serum Concentrations ...... in Hematological Malignancies.
@en
type
label
Superior Serum Concentrations ...... in Hematological Malignancies.
@ast
Superior Serum Concentrations ...... in Hematological Malignancies.
@en
prefLabel
Superior Serum Concentrations ...... in Hematological Malignancies.
@ast
Superior Serum Concentrations ...... in Hematological Malignancies.
@en
P2093
P2860
P356
P1476
Superior Serum Concentrations ...... in Hematological Malignancies
@en
P2093
Aaron Cumpston
Abraham S Kanate
Mehdi Hamadani
Michael Craig
Ryan Caddell
Xiaoxiao Lu
P2860
P304
P356
10.1128/AAC.00581-15
P407
P577
2015-05-18T00:00:00Z